1. To learn that somatic tumor sequencing panels frequently identify patients at risk for hereditary hematopoietic malignancies despite not being designed for this purpose.
2. To understand the role of unbiased sequencing studies for syndrome discovery in the field of hereditary hematopoietic disorders.
3. To learn about the role of clonal hematopoiesis as a potential risk factor for clinical progression in patients with hereditary hematopoietic disorders.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation